Do Surface Modifying Additives (SMA) Influence Blood Loss and Thrombogenicity in Conventional Cardiopulmonary Bypass for Coronary Artery Bypass Grafting?

Vascular

Volumn 11, Issue 2, 2003, Pages 159-163

  Martens, S ^a   Matheis, G ^a   Wimmer Greinecker, G ^a   Scherer, M ^a   Doss, M ^a   Moritz, A ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

cardiopulmonary bypass; coagulation; fibrinolysis; surface modification

Indexed keywords

ANTIPLASMIN; COPOLYMER; PROTHROMBIN; SURFACE MODIFYING ADDITIVE; THROMBIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOCOMPATIBILITY; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOUBLE BLIND PROCEDURE; FEMALE; FIBRINOLYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOGENICITY;

EID: 0037379604     PISSN: 17085381     EISSN: None     Source Type: Journal    
DOI: 10.1177/096721090301100210     Document Type: Article

References (20)

1. Stammers, A. H. Historical aspects of cardiopulmonary bypass: From antiquity to acceptance. Journal of Cardiothoracic and Vascular Anesthesia, 1997, 64, 1540-1543.
2. Daniel, S. Review of the multifactorial aspects of bioincompatibility in CPB. Perfusion, 1996, 11, 246-255.
3. Voorhees, M. E. and Tsai, C. C. State-of-the-art approaches for blood compatibility. Proceedings of the American Academy of Cardiovascular Perfusion, 1992, 13, 130-134.
4. Gott, V. L. Whiffen, J. D. and Dutton, R. C. Heparin bonding on colloidal surfaces. Science, 1963, 142, 1297-1298.
5. von Segesser, L. K. Weiss, B. M. Garcia, E. et al. Reduction and elimination of systemic heparinization during cardiopulmonary bypass. Journal of Thoracic and Cardiovascular Surgery, 1992, 103, 190-199.
6. Boonstra, P. W. Gu, Y. J. Akkerman, C. et al. Heparin coating of an extracorporeal circuit partly improves hemostasis after cardiopulmonary bypass. Journal of Thoracic and Cardiovascular Surgery, 1994, 107, 289-292.
7. Videm, V. Svennevig, J. L. and Fosse, E. Reduced complement activation with heparin coated oxygenator and tubings in coronary bypass operations. Journal of Thoracic and Cardiovascular Surgery, 1992, 103, 806-813.
8. Martens, S. Wimmer-Greinecker, G. Matheis, G. et al. Heparinbeschichtung des extrakorporalen kreislauf: Gerinnungsaktivierung, verbrauch und fibrinolyse in einer randomisierten studie an koronarbypasspatienten. Zeitschrift für Herz-, Thorax- und Gefäßchirurgie, 1999, 13, 267-272.
9. Wimmer-Greinecker, G. Matheis, G. Martens, S. et al. Synthetic protein treated versus heparin coated cardiopulmonary bypass surfaces: Similar clinical results and minor biochemical differences. European Journal of Cardiothoracic Surgery, 1999, 16, 211-217.
10. te Velthuis, H. Baufreton, C. Jansen, P. G. M. et al. Heparin coating of extracorporeal circuits inhibits contact activation during cardiac operations. Journal of Thoracic and Cardiovascular Surgery, 1997, 114, 117-122.
11. Tsai, C. C. Deppisch, R. M. Forrestal, L. J. et al. Surface modifying additives for improved device-blood compatibility. ASAIO Journal, 1994, 40 (3), 619-624.
12. Gu, Y. J. Boonstra, P. W. Rijnsburger, A. A. et al. Cardiopulmonary bypass circuit treated with surface-modifying additives: A clinical evaluation of blood compatibility. Annals of Thoracic Surgery, 1998, 65, 1342-1347.
13. Bossant, M. J. Ninio, E. Delautier, D. et al. Bioassay of pafacether by rabbit platelet aggregation. Methods in Enzymology, 1990, 187, 125-129.
14. Rubens, F. D. Labow, R. S. Lavallee, G. R. et al. Hematologic evaluation of cardiopulmonary bypass circuits prepared with a novel block copolymer. Annals of Thoracic Surgery, 1999, 67, 689-698.
15. Rubens, F. D. Ruel, M. Lavallee, G. et al. Circuits with surface modifying additive alter the hemodynamic response to cardiopulmonary bypass. European Journal of Cardio thoracic Surgery, 1999, 15, 353-358.
16. Bachmann, F. McKenna, R. Cole, E. R. et al. The hemostatic mechanism after open heart surgery. Studies on coagulation factors and fibrinolysis in 512 patients after extracorporeal circulation. Journal of Thoracic and Cardiovascular Surgery, 1975, 70, 76-85.
17. Gralnik, H. R. and Fischer, R. D. The hemostatic response to open heart operations. Journal of Thoracic and Cardiovascular Surgery, 1971, 61, 909-915.
18. Wüst, T. Beeser, H. Lang, H. R. et al. Diagnostik und therapie der verbrauchs-koagulopathie. Intensivmedizin, 1990, 27, 177-182.
19. Wieding, J. U. Eisinger, G. and Köstering, H. Diagnostik der disseminierten intravasalen Gerinnung: Aussagekraft von löslichem Fibrin, D-Dimeren und Fibrin(ogen)- Spaltprodukten. Klinische Wochenschrift, 1989, 67, 764-773.
20. Parolari, A. Alamanni, F. Gherli, T. et al. “High dose” aprotinin and heparin coated circuits: Clinical efficacy and inflammatory response. Cardiovascular Surgery, 1999, 7 (1), 117-127.